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Abstract
Background: The role of radiation therapy in addition to chemotherapy has not been well established in non-
oligometastatic Stage IV non-small cell lung cancer (NSCLC). We aimed to investigate overall survival (OS) of non-
oligometastatic Stage IV NSCLC treated with chemotherapy with concurrent radiation to the primary tumor.
Methods: Eligible patients were screened from two prospective studies. Oligometastatic and non-oligometastatic
NSCLC were defined as having < 5 and ≥5 metastatic lesions, respectively. Prognostic factors for OS were identified
by using univariate and multivariate analysis. Landmark analysis and propensity-score matching (PSM) were each
performed to further adjust for confounding.
Results: A total of 274 patients were identified as the study cohort: 183 had non-oligometastatic disease. For all
274 patients, those who received a radiation dose ≥63 Gy to the primary tumor and had oligometastatic disease
had better OS (P < 0.001 and P = 0.017, respectively). When patients were subdivided into those with
oligometastatic or non-oligometastatic disease, a radiation dose ≥ 63 Gy remained a significant prognostic factor for
better OS. For non-oligometastatic patients, multivariate analysis showed that receiving ≥63 Gy radiation, having a
GTV <146 cm3, having response to chemotherapy, and having stable or increased post-treatment KPS
independently predicted better OS (P = 0.018, P = 0.014, P = 0.014, and P = 0.001). After PSM in non-oligometastatic
patients, a higher radiation dose (≥63 Gy) remained to be correlated with better OS. By landmark analysis,
aggressive radiation (≥63 Gy) remained to be correlated with better OS in Pre-PSM cohort (P = 0.005) and Post-PSM
cohort (P = 0.004).
Conclusions: Radiation dose, primary tumor volume, response to chemotherapy and KPS after treatment are
associated with OS in patients with non-oligometastatic disease; on basis of effective system chemotherapy,
aggressive thoracic radiotherapy may prolong OS.
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Background
Approximately 60% of patients who have been newly di-
agnosed with non-small cell lung cancer (NSCLC) have
distant metastases [1]. The metastatic status of NSCLC
are highly variable, which ranges from the presence of a
single metastatic lesion to a single organ to multiple le-
sions in several organs. Hellman et al. [2] proposed a no-
tion is that of oligometastases in 1995, oligometastases is
the state in which the patient shows distant metastase
are limited in number and locations. In addition to oli-
gometastases, there are many other patients who have
extensive and widespread metastases, this metastatic
state might be called "non-oligometastases".
In the era of two-dimensional radiotherapy (2D-RT),
thoracic radiotherapy has long been used as a palliative
care in metastatic NSCLC [3–5]. Recent years, there is in-
creasing evidence showed that patients presenting with
oligometastatic NSCLC could benefit from aggressive
thoracic radiotherapy beyond palliative irradiation [6–12].
However, there was no consistent definition of oligome-
tastases in these studies.
Although, the term of oligometastatic NSCLC has
been used without a consistent definition. In recent
years, the general opinion is that patients with 1-5
metastases is oligometastases [7–9, 13]. In general con-
sideration, pharmacotherapy was the main treatment
modality, and, radiation to primary tumor not affect
survival and should be only given to alleviate symptoms
(hemoptysis, cough, pain, and others) in non-
oligometastatic Stage IV NSCLC. Thus, research on the
treatment modalities for non-oligometastatic NSCLC
have mainly focused on pharmacotherapy over the years.
Nearly 30% of patients may benefit from molecular tar-
geted therapy [14, 15]. Thus, approximately 70% of
patients require system chemotherapy. However, the effi-
cacy of platinum-based combination chemotherapy may
have reached a plateau over the past 10-15 years [16, 17].
Radiation to the primary tumor for oligometastatic
NSCLC patients, who had <5 metastases, has produced
favorable survival outcomes [7–10, 13]. In the early
years, published data have indicated that the combin-
ation of thoracic radiotherapy and chemotherapy
improved the treatment outcomes for limited-stage
small-cell lung cancer (SCLC) patients [18, 19]. Recently,
a phase 3 randomized controlled trial showed thoracic
radiotherapy also improves OS for patients with
extensive-stage SCLC who have responded to chemo-
therapy [20]. The remained question is that whether or
not thoracic radiation therapy in addition to chemother-
apy is beneficial for overall survival in patients with non-
oligometastatic NSCLC (who had ≥5 metastases), like
extensive SCLC. Therefore, we collected clinical data
from two prospective studies to analyze the survival out-
comes of non-metastatic NSCLC patients who had
undergone concurrent chemotherapy with three-
dimensional radiation therapy (3D-RT) to primary




We selected patients presenting with metastaic NSCLC
who were enrolled in two prospective studies from Janu-
ary 2003 and May 2012 [11, 12]. The selection criteria
were as follows: (1) histologically or cytology confirmed
NSCLC; (2) newly diagnosed stage IV disease (staged
according to the 2002 system of the American Joint
Committee on Cancer); (3) did not receive targeted ther-
apy or immunotherapy during lifetime; (4) age 18-80
years; (5) a Karnofsky Performance Status (KPS) score
≥70%; (6) received at least two chemotherapy cycles and a
thoracic radiation dose of at least 36 Gy in 1.8 to 2-Gy frac-
tions; (7) using modern radiation technique (3-dimensional
conformal radiation therapy [3DCRT] or intensity modu-
lated radiation therapy [IMRT]) and (8) had complete med-
ical records ( include sex, age, KPS score, tumor histology,
N stage, T stage, metastatic status at diagnosis, radiation
therapy to primary tumor, treatment response, and having
survival outcomes [dead or alive]). This study was reviewed
by the ethical review boards in China (Ethics Committee of
Guizhou Cancer Hospital, GuiYang, China), and the
informed consent was obtained from all patients.
Definition of oligometastatic and non-oligometastatic
disease
The definition of oligometastatic and non-oligometastatic
disease in NSCLC varies across studies, which ranges from
the presence of a single metastatic lesion to a single organ
in some studies to multiple lesions in several organs in
others [6, 7, 9, 11, 21, 22]. In our current study, we defined
oligometastatic and non-oligometastatic NSCLC accord-
ing to the number of metastatic lesions; namely that < 5
metastatic lesions was defined as oligometastatic NSCLC,
and ≥5 metastatic lesions was defined as non- oligometa-
static NSCLC.
Pretreatment evaluations
All patients underwent fiberoptic bronchoscopy and
contrast-enhanced computed tomography (CT) of the
chest to evaluate the extent of the primary tumor and
regional lymph node status. All patients also underwent
bone scintigraphy, contrast-enhanced CT of the abdom-
inal region, and magnetic resonance imaging (MRI) of
the brain to detect distant metastases. Positive findings
on positron emission tomography (PET) /CT or bone
scintigraphy required other additional radiologic con-
firmation (e.g., MRI or CT of bone). Pretreatment
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All select patients received thoracic radiation dose of at
least 36 Gy in 1.8-2-Gy fractions. Radiation to primary
tumor was implemented by modern techniques (3D-
CRT or IMRT). Radiation therapy was given concur-
rently with the chemotherapy, beginning within 1 week
after beginning the first course of chemotherapy. Details
of the radiation therapy protocol have been reported
previously [11, 12].
Chemotherapy
Platinum-based doublet chemotherapy (cisplatin in com-
bination with docetaxel, paclitaxel, pemetrexed, or vino-
relbine), given every 21-28 days concurrent with
thoracic radiation therapy, was the first-line therapy for
all patients. No induction chemotherapy was given prior
to radiation. After thoracic radiotherapy was completed,
patients demonstrating response or stable disease con-
tinued chemotherapy for a total of 4-6 cycles. No main-
tenance therapy was given.
Evaluation of treatment response
The treatment responses of tumors, including complete
response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD), were evaluated according
to the Response Evaluation Criteria in Solid Tumors sys-
tem [23]. To evaluate treatment response of radiother-
apy: CR or PR was evaluated as having response,
whereas SD or PD as no response. However, to evaluate
treatment response of chemotherapy: no change in size
or shrinkage in any size of target lesions was evaluated
as having response to chemotherapy, whereas increasing
in any size of target lesions as no response.
Statistical analyses
The endpoints of this study was to evaluate overall sur-
vival (OS). The OS time was measured from the starting
date of treatment. Statistical tests were done with Stata,
version 11.2 software. The Kaplan-Meier method was
used to calculate the OS, and the curves were compared
with log–rank tests. Multivariate Cox regression analysis
was used to identify the independent predictors of OS.
All significant factors in univariate analysis were further
tested in the multivariate analysis. Propensity-score
matching (PSM) and landmark analysis requiring a mini-
mum of 8 months OS were each performed in sensitivity
studies to further adjust for confounding. All statistical
tests were two-sided, and P values < 0.05 were consid-
ered to indicate statistical significance.
Results
Overall treatment outcomes
Totally, 274 eligible patients were included in this study,
91 patients had oligometastatic disease and 183 had
non-oligometastatic disease. The follow-up period
ranged from 2.0 to 64.0 months; at the time of last
follow-up, 15 patients were still alive, and the median
survival time for those patients was 40.0 months (range,
12.0–64.0 months). The median OS time for all patients
was 13.0 months (95% CI 11.9–14.1), and the OS rates
were 50.7% at 1 year, 15.8% at 2 years, and 9.1% at
3 years. OS rates for patients who had received ≥63 Gy
Fig. 1 Overall survival grouped by state of metastatic disease (oligometastases and non-oligometastases)
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thoracic radiation therapy were 55.3% at 1 year, 22.7% at
2 years, and 17.0% at 3 years; corresponding rates for
those who received <63 Gy were 46.5%, 9.3%, and
2.5%(χ2 = 15.638, P < 0.001).
Comparison of OS in patients with oligometastatic dis-
ease versus those with non- oligometastatic disease, pa-
tients with oligometastatic disease had a better OS. The
median survival time (MST) for these two groups were
14.0 months (95% CI, 11.25 – 16.75) and 12.0 months
(95% CI, 10.59 – 13.41); the 1-, 2-, and 3-year OS rates
were 59.3%, 22.0%, and 15.2% versus 46.4%, 12.7%, and
6.0% (χ2 = 5.741, P = 0.017), (Fig. 1). When the whole
group was subdivided into those with oligometastases
(χ2 = 6.150, P = 0.013) or non-oligometastases (χ2 =
8.257, P = 0.004), thoracic radiation dose ≥63 Gy
remained a prognostic factor for better overall survival.
Survival analysis of non-oligometastatic Stage IV patients
Seventy-eight patients had metastasis in only one organ:
28 in the bone, 21 in the lung, 23 in the brain, and 6 in
other locations. One hundred and five patients had me-
tastasis in two or three organs, the most common site of
metastatic disease at diagnosis was the bone (70 of 105
patients), 57 patients had lung metastasis, 51 had
Table 1 Characteristics of the non-oligometastatic patient cohort before and after PSM
Variable Pre-PSM Cohort Post-PSM Cohort
<63 Gy ≥63Gy P value <63 Gy ≥63Gy P value
Total 93 90 59 59
Gender
Male 66 59 0.431 47 38 0.065
Female 27 31 12 21
Age (years)
<60 years 52 48 0.726 31 27 0.461
≥60 years 41 42 28 32
KPS Score
≤80 58 52 32 32
>80 35 38 0.526 27 27 1.000
Pathological type
Squamous carcinoma 35 24 0.048 24 20 0.651
adenocarcinoma 47 61 30 35
Other 11 5 5 4
T status
T1-2 33 36 0.529 19 22 0.562
T3-4 60 54 40 37
N status
N0-1 11 14 0.463 5 12 0.066
N2-3 82 76 54 47
Response to chemotherapy
Yes 64 68 43 43 1.000
No 29 22 0.309 16 16
No. of chemotherapy cycles
<4 63 32 <0.001 30 30 1.000
≥4 30 58 29 29
GTV volume (cm3)
<146 44 40 0.697 23 23 1.000
≥146 49 50 36 36
Metastasis status
Single organ 37 41 0.430 23 27 0.456
2 to 3 organs 56 49 36 32
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metastasis in brain, 16 had metastasis in adrenal, 12 pa-
tients had metastasis in distant lymph nodes, six had
subcutaneous nodules, and 12 in other locations. Clin-
ical characteristics of non- oligometastatic NSCLC pa-
tients are listed in Table 1.
At the time of analysis, 41 of 183 non-oligometastatic
Stage IV patients died of unknown causes. The cause of
death of the remaining142 patients were as follows: most
patients died with distant metastasis, only 9 of 142
(6.3%) patients died with primary recurrence alone, 95
(67.0%) patients died with distant metastasis, 13 (9.2%)
patients died with distant metastasis and primary recur-
rence, 12 (8.4%) patients died of other medical disease, 3
(2.1%) patients died with treatment complication, and 10
(7.0%) patients was alive. Univariate analysis showed that
radiation dose to the primary tumor (Fig. 2), primary
tumor volume, post-treatment KPS score, the number of
chemotherapy cycles, and having a treatment response
to chemotherapy were significantly associated with OS
(Table 2). Multivariate analysis showed that radiation
dose, primary tumor volume, post-treatment KPS score,
and the treatment response to chemotherapy were sig-
nificantly associated with OS, as shown in Table 3.
In subgroup analyses, we observed that radiation dose
also interacted with treatment response to chemotherapy
and primary tumor volume in terms of influencing OS.
Total1y, 72.1% (132/183) patients were confirmed to
have responded to chemotherapy, and 27.9% (51/183)
patients have no response to chemotherapy. Among
patients who had a response to chemotherapy, patients
who received ≥63 Gy to the primary tumor had a better
OS than those received < 63 Gy (χ2 = 4.419, P = 0.036);
patients who had no response to chemotherapy,
radiation doses was not correlated with OS (χ2 = 1.947,
P = 0.163), Fig 3. Patients with GTV <146 cm3, radiation
dose to primary tumor was not associated with OS (χ2 =
1.248, P = 0.264); among patients with GTV ≥146 cm3, a
higher radiation dose (≥63 Gy) remained beneficial for
OS (χ2 = 7.897, P = 0.005), Fig 4.
Propensity score analysis of the impact of radiation dose
on OS in non-oligometastatic Stage IV patients
The patient selection factors used to estimate the pro-
pensity score were KPS scores, GTV volume, number of
chemotherapy cycles and response to chemotherapy.
Table 1 summarizes the non-oligometastatic patient
characteristics before and after PSM. Before PSM, there
were significant differences in pathological type and the
number of chemotherapy cycles between the groups that
received < 63 Gy and ≥ 63 Gy. After PSM, all clinical
characteristic were balanced between the two radiation
arms. The 1:1 propensity score–matched cohort con-
sisted of 118 patients with non-oligometastatic disease.
In the post-PSM cohort, radiation dose to the primary
tumor, having a treatment response to chemotherapy,
and post-treatment KPS score a1so remained to be asso-
ciated with OS, and the number of chemotherapy cycles
had a trend for better OS by univariate analysis (Table 2).
On multivariate analysis, these factors retained signifi-
cance with regard to OS, as shown in Table 3. On
landmark analysis for patients surviving at least
8 months, patients who received ≥ 63 Gy to primary
tumor retained significance with better OS in Pre-
PSM cohort (χ2 = 7.953, P = 0.005) and post-PSM
cohort (χ2 = 8.157, P = 0.004).
Fig. 2 Overall survival in non-oligometastases patients according to radiation dose
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Survival analysis of oligometastatic Stage IV patients
Among 91 oligometastatic Stage IV patients: most
patients died with distant metastasis, only 11 (12.1%)
patients died with primary recurrence alone, 43 (47.3%)
patients died with distant metastasis, 15 (16.5%) patients
died with distant metastasis and primary recurrence, 5
(5.5%) patients died of other medical disease, 12 (13.2%)
died of unknown causes, and 5 (5.5%) patients was alive.
Univariate analysis showed that radiation dose to the
primary tumor (χ2 = 6.150, P = 0.013), primary tumor
volume (χ2 = 5.433, P = 0.020), post-treatment KPS score
(χ2 = 4.730, P = 0.030), the number of chemotherapy
Table 2 Univariate analysis for OS in non-oligometastatic patients
Variable Pre-PSM Cohort Post-PSM Cohort
No 1-yr 2-yr 3-yr Statistic value No 1-yr 2-yr 3-yr Statistic value
Gender
Male 125 41.6 12.8 4.3 χ2 = 1.804 85 36.5 11.8 3.5 χ2 = 2.153
Female 58 56.9 12.4 7.8 P = 0.179 33 7.6 12.1 6.1 P = 0.142
Age (years)
<60 100 48.0 11.0 3.7 χ2 = 0.009 58 44.8 12.1 4.0 χ2 = 0.295
≥60 83 44.6 14.9 7.4 P = 0.926 60 40.0 11.7 6.7 P = 0.587
Tumor histology
Adenocarcinoma 108 52.8 14.1 6.4 χ2 = 2.777 65 41.5 12.3 6.6 χ2 = 0.443
Squamous carcinoma 59 37.3 10.2 5.1 P = 0.250 44 40.9 9.1 4.5 P = 0.801
others 16 37.5 12.5 0.0 9 55.6 11.1 0.0
Pre-treatment KPS
70-80 110 49.1 12.0 5.6 χ2 = 0.255 64 43.8 7.8 4.7 χ2 = 0.001
>80 73 42.5 13.7 4.3 P = 0.614 54 40.7 16.7 5.2 P = 0.976
T stage
T1-2 69 50.7 11.9 5.0 χ2 = 0.018 41 39.0 9.8 4.9 χ2 = 0.862
T3-4 114 43.9 13.2 4.8 P = 0.914 77 44.2 13.0 5.4 P = 0.353
N stage
N0-1 25 68.0 21.3 11.3 χ2 = 3.696 17 64.7 17.6 17.6 χ2 = 3.242
N2-3 158 43.0 11.4 4.5 P = 0.055 101 38.6 10.9 3.6 P = 0.072
Gross tumor volume, cm3
<146 90 59.2 17.5 6.7 χ2 = 7.319 46 50.0 10.9 4.3 χ2 = 0.618
≥146 93 37.6 9.7 4.2 P = 0.007 72 37.5 12.5 6.2 P = 0.432
Post-treatment KPS
Increased or stable 151 52.3 14.8 5.9 χ2 = 15.807 95 47.4 13.7 5.7 χ2 = 6.011
Decreased 32 18.8 3.1 3.1 P = 0.000 23 21.7 4.3 4.3 P = 0.014
Radiation dose, Gy
≥63 90 51.1 21.1 11.2 χ2 = 8.257 59 47.5 20.3 10.8 χ2 = 7.013
<63 93 41.9 6.6 0.0 P = 0.004 59 37.3 3.4 0 P = 0.008
Chemotherapy cycles
<4 95 37.9 8.7 2.5 χ2 = 5.334 60 31.7 6.7 4.4 χ2 = 3.775
≥4 88 55.7 1.7 8.3 P = 0.021 58 53.4 17.2 6.5 P = 0.052
Metastasis status
Single organ 78 46.2 16.7 8.3 χ2 = 1.622 50 46.0 18.0 8.0 χ2 = 2.739
2 to 3 organs 105 46.7 9.7 2.9 P = 0.203 68 39.7 7.4 3.7 P = 0.098
Response to chemotherapy
No 51 25.5 7.8 3.9 χ2 = 10.428 32 21.9 6.2 3.1 χ2 = 6.230
Yes 132 54.5 14.6 5.9 P = 0.001 86 50.0 14.0 6.1 P = 0.013
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cycles (χ2 = 4.384, P = 0.036), and having a treatment re-
sponse to chemotherapy (χ2 = 7.444, P = 0.006) were sig-
nificantly associated with OS. Multivariate analysis
showed that radiation dose (P = 0.047), and primary
tumor volume (P = 0.015) predicted OS in these patients
with oligometastatic Stage IV NSCLC.
Discussion
This study sought to investigate whether combining sys-
temic chemotherapy with radiation to the primary tumor
could further improve OS of non-oligometastatic Stage
IV NSCLC. Compared with historical data [16, 24], this
combined therapy in current study produce favorable
overall survival. Consistent with previous publication
[9], we found that oligometastatic disease and aggres-
sive radiation to the primary tumor were associated
with better OS. When the entire group was divided
according to metastatic status (oligometastases vs.
non-oligometastases), aggressive radiation doses to the
primary tumor retained significance for predicting im-
proved survival outcomes.
Consistent with the conclusion of previous studies
[7, 9, 10], we found that radiation dose, and primary
tumor volume predicted survival in these patients
with oligometastatic disease. Among patients with
non-oligometastatic disease, defined as ≥5 metastases,
we found that receiving higher radiation dose to pri-
mary tumor, having a smaller GTV, having response
to chemotherapy, and having stable or increased post-
treatment KPS scores independently predicted better
OS. Most of these predicted factors have been identi-
fied in the literature as positive prognostic factors in
oligometastatic NSCLC [7–9, 12, 25].
Non-oligometastatic NSCLC patients who are judged
to be incurable and have a very short life expectance,
radiation is most typically used as palliative treatment
Table 3 Multivariate analyses for OS in non-oligometastatic patient
Variable Pre-PSM Cohort Post-PSM Cohort
HR 95.0% confidence interval P value HR 95.0% confidence interval P value
lower upper lower upper
Radiation dose, Gy
(<63 vs. ≥63)
1.481 1.071 2.047 0.018 1.656 1.125 2.438 0.011
Response to chemotherapy
(No vs. Yes)
1.541 1.092 2.176 0.014 1.643 1.073 2.517 0.022
Post-treatment KPS
(Decreased vs. Increased or stable)
1.958 1.319 2.907 0.001 1.704 1.064 2.729 0.026
No. of chemotherapy cycles
(≥4 vs. <4)
0.796 0.572 1.106 0.173 - - - -
Gross tumor volume, cm3
(≥146 vs. <146)
1.479 1.082 2.021 0.014 - - - -
Fig. 3 Overall survival according to radiation dose and treatment response of chemotherapy
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when symptoms (hemoptysis, cough, chest pain, dys-
pnea, and others) emerge. Recent years, there is increas-
ing evidence that selected oligometastatic NSCLC
patients could benefit from aggressive thoracic radio-
therapy beyond palliative irradiation [7–9, 11, 21, 22].
Comparatively speaking, published studies concerning
radiation doses (aggressive or palliative) for non-
oligometastatic patients has been limited. In current
study, receiving ≥63 Gy to the primary tumor was an in-
dependent prognostic predictors of better OS.
Pharmacotherapy has been the main treatment modal-
ity, and still play an irreplaceable role for non-metastatic
NSCLC. In current study, having response to chemo-
therapy was an independent prognostic predictors of
better OS, and receiving ≥4 cycles chemotherapy was
marginally associated with better OS. When the entire
group was divided according to response to chemother-
apy, higher radiation doses to the primary tumor
retained significance for predicting improved survival
outcomes in patients who had response to chemotherapy.
For the subgroup that had no response to chemotherapy,
there was no benefit for improved OS at higher radiation
doses. Our findings suggest that non-oligometastatic
NSCLC patients benefit from higher radiation doses
(≥63 Gy) to the primary tumor based on effective systemic
chemotherapy. Thus, in clinical practice, higher radiation
dose may be apply in a patient cohorts who have treat-
ment response to effective system therapy. For non-
metastatic NSCLC patients who have no response to
system therapy, thoracic radiation therapy can be used for
palliative intent, whereas, high dose radiotherapy is an
unwise choice. In current study, radiation to primary
tumor was given concurrently with the chemotherapy. As
a result, we recommend further investigation on the value
of radiation to primary tumor following effective induc-
tion chemotherapy on non-oligometastatic NSCLC.
Recent years, molecular targeted therapy and immuno-
therapy produce favorable survival outcomes in meta-
static NSCLC patients [15, 26, 27]. Because no patients
in the current study received molecular targeted therapy
or immunotherapy, we cannot comment on whether
thoracic radiation combined with molecular targeted
therapy or immunotherapy would affect survival. Thus,
additional studies are also necessary to investigate the
value of thoracic radiation in combination with targeted
therapy or immunotherapy for patients with non-
oligometastatic NSCLC.
From a clinical standpoint, the larger primary tumor is
an indication of a greater tumor burden and source of me-
tastasis, and makes the tumor more difficult to control
[28, 29]. Our finding suggest that non-oligometastatic
NSCLC patients with smaller primary tumor volume had
better OS, consistent with the impact of primary tumor
burden on OS for oligometastatic NSCLC [7, 8]. In
addition, among patients with larger GTV (≥146 cm3), a
higher radiation dose (≥63 Gy) remained beneficial for
OS; whereas, survival benefit was not observed with
higher radiation dose in patients with GTV <146 cm3.
Our findings suggest that the volume of primary tumor
may be used as an indicator to decide radiation dose to
primary tumor. We found that stable or increased post-
treatment KPS scores were independent predictors of
better survival. This finding suggests that post-treatment
performance status should be maintained or improved;
thus, overtreatment should be avoided when treating non-
oligometastatic NSCLC with multimodality therapy.
Fig. 4 Overall survival according to radiation dose and primary tumor volume
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We acknowledge several limitations of our study. First,
consistent imaging data were not gained in a proportion
of patients for the evaluation of the relationship between
OS and control of primary tumor. Higher radiation
doses are associated with improved local tumor control
[30]. Although we did not obtain data regarding local
control in this study, we speculate that aggressive radi-
ation to primary tumor can improve OS by improving
control of primary tumor to reduce the death rate
caused by local growth of tumor and decrease the
sources of metastasis. Second, the choice of the radiation
dose may depend on some factors such as KPS and
tumor burden. Although PSM, multivariate regression
and landmark analysis were used to reduce this bias,
some unaccounted confounders could still have existed
between the treatment groups because of the retrospect-
ive nature of this study. Therefore, further evidence is
needed to confirm conclusions of this study.
Conclusions
Patients with non-oligometastatic Stage IV NSCLC with
good performance status who were treated with aggres-
sive radiation doses (≥63 Gy) to the primary tumor had
improved survival outcomes. However, patients benefit
from aggressive radiation doses (≥63 Gy) to the primary
tumor based on having had response to effective system
chemotherapy. Thus, in addition to systemic chemo-
therapy, we should consider proper radiation dose to
primary tumor. Among patients with larger tumors,
high radiation dose remained of benefit for OS, and
primary tumor volume may be used as an criteria to
decide radiation dose. Furthermore, the studies on radi-
ation to primary tumor in non-oligometastatic NSCLC
has been limited; and further studies, especially pro-
spective studies, are needed to confirm the outcomes of
this treatment modality.
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